You’re in the driver’s seat
Get a clear view of your patients’ treatment options with complete biomarker testing
Know the road ahead
Test for ALL recommended biomarkers to map out the best route
See the signs
The treatment landscape is rapidly changing
Biomarker testing is driving a new standard of care
Backed by leading cancer research and advocacy organizations, the Clear Your View initiative aims to ensure complete biomarker testing informs treatment decisions for every advanced cancer patient.
Use results to determine the best treatment plan
New targeted therapies are extending survival for patients with advanced cancers
Patients with targetable alterations respond better to targeted therapy than immunotherapy1
Incomplete testing can lead to sub-optimal patient outcomes
Targeted Therapy
50-83%
Response Rates
Immunotherapy
4-26%
Response Rates
Overall Response, Targeted Therapy vs. Immunotherapy
60%
of CRC patients have a mutation that means anti-EGFRs will not work to treat their disease8
72% of advanced CRC patients who received anti-EGFR therapy did not have RAS and BRAF testing8
Roadmap to complete biomarker testing
STOP
Test every patient for all recommended biomarkers
WAIT
for complete biomarker results
TREAT
with the best possible therapies
Patients Are Asking
“What is stopping you from testing all of your lung cancer patients?”
“Do you have all the results before starting my first line treatment?”
Growing patient awareness
A thriving community of patient organizations advocate for complete testing before treatment
